DOI QR코드

DOI QR Code

Absorption Enhancer and Polymer (Vitamin E TPGS and PVP K29) by Solid Dispersion Improve Dissolution and Bioavailability of Eprosartan Mesylate

  • Received : 2011.03.02
  • Accepted : 2011.03.22
  • Published : 2011.05.20

Abstract

The aim of the present study was to improve the solubility and bioavailability of a poorly water-soluble drug in human body, using a solid dispersion technique (hot melt extrusion). The solid dispersion was prepared by cooling the hot melt of the drug in the carrier (Vitamin E TPGS and PVP). The dissolution rate of formulation 1 from a novel formulation prepared by solid dispersion technique was equal to release of formulation 6 (40% of eprosartan mesylate is in contrast to teveten$^{(R)}$) within 60 min (Table 1). The oral bioavailability of new eprosartan mesylate tablet having vitamin E TPGS and PVP K29 was tested on rats and dogs. Of the absorption enhancer and polymer tested, vitamin E TPGS and PVP K29, resulted in the greatest increases of AUC in animals (about 2.5-fold increase in rat and dog). When eprosartan mesylate was mixed with the absorption enhancer and polymer in a ratio of 2.94:2:1, vitamin E TPGS and PVP K29 improved eprosartan mesylate bioavailability significantly compared with the conventional immediate release (IR) tablet Teveten$^{(R)}$ (formulation 7). These results show that solid dispersion using vitamin E TPGS and PVP K29 is a promising approach for developing eprosartan mesylate drug products.

Keywords

References

  1. Plosker, G. L.; Foster, R. H. Drugs 2003, 60, 177.
  2. McClellan, K. J.; Balfour, J. A. Drugs 1998, 55, 713. https://doi.org/10.2165/00003495-199855050-00011
  3. Tenero, D.; Martin, D.; Ilson, B.; Jushchyshyn, J.; Boike, S.; Lundberg, D.; Zariffa, N.; Boyle, D.; Jorkasky, D. Biopharm. Drug. Dispos. 1998, 19, 351. https://doi.org/10.1002/(SICI)1099-081X(199809)19:6<351::AID-BDD115>3.0.CO;2-V
  4. Chapelsky, M. C.; Martin, D. E.; Tenero, D. M.; Ilson, B. E.; Boike, S. C.; Etheredge, R.; Jorkasky, D. K. J. Clin. Pharmacol. 1998, 38, 34. https://doi.org/10.1002/j.1552-4604.1998.tb04374.x
  5. Hedner, T.; Himmelmann, A. Am. J. Hypertens. 1997, 10, 119A.
  6. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Hyatt, J.; Navarro, L.; Edgar, K. J.; Schaefer, U. F.; Lehr, C. M. J. Control. Release. 2006, 111, 35. https://doi.org/10.1016/j.jconrel.2005.11.005
  7. Repka, M. A.; McGinity, J. W. Int. J. Pharm. 2000, 202, 63. https://doi.org/10.1016/S0378-5173(00)00418-X
  8. Chokshi, R. J.; Sandhu, H.; Iyer, R. M.; Shah, N. H.; Malick, A. W.; Zia, H. J. Pharm. Sci. 2005, 11, 2463.
  9. Leuner, C.; Dressman, J. Eur. J. Pharm. Biopharm. 2000, 50, 47. https://doi.org/10.1016/S0939-6411(00)00076-X
  10. Chiou, W. L.; Riegelman, S. J. Pharm. Sci. 1971, 60, 1281. https://doi.org/10.1002/jps.2600600902
  11. Zhang, F.; McGinity, J. W. Pharm. Dev. Technol. 1999, 4, 241. https://doi.org/10.1081/PDT-100101358
  12. Zhang, F.; McGinity, J. W. Drug Develop. Ind. Pharm. 2000, 26, 931. https://doi.org/10.1081/DDC-100101320
  13. Ching, C. C. 2006, PCT patent 052461.
  14. Li, X. N.; Xu, H. R.; Chen, W. L.; Liu, G. Y.; Chu, N. N.; Yu, C. J. Chrom. B 2007, 853, 47. https://doi.org/10.1016/j.jchromb.2007.02.049
  15. Kim, H.; Yoo, J. Y.; Han, S. B.; Lee, H. J.; Lee, K. R. J. Pharm. Biomed. Anal. 2003, 32, 209. https://doi.org/10.1016/S0731-7085(03)00059-1
  16. Wen, A.; Hang, T.; Chen, S.; Wang, Z.; Ding, L.; Tian, Y.; Zhang, M.; Xu, X. J. Pharm. Biomed. Anal. 2008, 48, 829. https://doi.org/10.1016/j.jpba.2008.05.032
  17. Li, C. J.; Higashiyama, K.; Yoshimura, Y.; Nagai, T.; Takayama, K.; Obata, Y. Biol. Pharm. Bull. 2001, 24, 1044. https://doi.org/10.1248/bpb.24.1044
  18. Obata, Y.; Sato, H.; Li, C. J.; Takayama, K.; Higashiyama, K.; Nagai, T.; Isowa, K. Int. J. Pharm. 2000, 198, 191. https://doi.org/10.1016/S0378-5173(00)00328-8

Cited by

  1. Polyvinylpyrrolidone Behavior in Water/Ethanol Mixed Solvents: Comparison of Modeling Predictions with Experimental Results vol.46, pp.7, 2017, https://doi.org/10.1007/s10953-017-0649-0